Blue Jet Healthcare COO On FY27 Growth, Margins & China+1 Opportunity

By NDTV Profit

Community Score: 50% | 99 views | 1w

0 community ratings: null thumbs up, null thumbs down

Blue Jet Healthcare reported a mixed first quarter, but management remains optimistic about FY27. COO VK Singh says the company is nearing the end of the de-stocking cycle in its pharma intermediates business and expects recovery to be supported by a strong order book, new product launches, contrast media growth and expanding CDMO opportunities. The company also highlighted opportunities in GLP-1, diagnostics, specialty sweeteners and the broader China+1 manufacturing trend while maintaining healthy margins. Watch the full breakdown of Blue Jet Healthcare's FY27 outlook. #BlueJetHealthcare #Pharma #CDMO #Healthcare #StockMarket #BusinessNews #India #ChinaPlusOne #GLP1 #ContrastMedia For more videos subscribe to our channel: https://www.youtube.com/@NDTVProfitIndia Visit NDTV Profit for more news: https://www.ndtvprofit.com/ Don't enter the stock market unaware. Read all Research Reports here: https://www.ndtvprofit.com/research-reports Follow NDTV Profit here Twitter: https://twit

Tags: Blue Jet Healthcare, Blue Jet Q1 Results, Blue Jet Healthcare Results, VK Singh, Blue Jet CEO, Pharma Stocks, Indian Pharma, CDMO India, Contrast Media, Pharma Intermediates, GLP1, China Plus One, Healthcare Stocks, Specialty Chemicals, Stock Market India, Business News, Earnings, Q1 FY27, Blue Jet Share, NDTV Profit